A new trading day began on Friday, with Q32 Bio Inc (NASDAQ: QTTB) up 10.19% from the previous day of trading, before settling in for the closing price of $3.24. QTTB’s price has ranged from $1.35 to $53.17 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 31.75% over the last five years. Meanwhile, its annual earnings per share averaged 50.53%. With a float of $4.46 million, this company’s outstanding shares have now reached $12.20 million.
Q32 Bio Inc (QTTB) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Q32 Bio Inc is 63.42%, while institutional ownership is 15.47%. The most recent insider transaction that took place on Aug 26 ’25, was worth 18,900. In this transaction CEO of this company sold 10,494 shares at a rate of $1.80, taking the stock ownership to the 121,506 shares. Before that another transaction happened on Aug 26 ’25, when Company’s Chief Scientific Officer sold 2,990 for $1.80, making the entire transaction worth $5,385. This insider now owns 58,384 shares in total.
Q32 Bio Inc (QTTB) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.46 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.09% during the next five years compared to 31.75% growth over the previous five years of trading.
Q32 Bio Inc (NASDAQ: QTTB) Trading Performance Indicators
Here are Q32 Bio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.30, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.38 in one year’s time.
